Lumacaftor Plus Ivacaftor Combination + Ivacaftor
Phase 3CompletedDevelopment Stage
Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation
Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation
Oct 1, 2013 → Apr 1, 2016
About Lumacaftor Plus Ivacaftor Combination + Ivacaftor
Lumacaftor Plus Ivacaftor Combination + Ivacaftor is a phase 3 stage product being developed by Vertex Pharmaceuticals for Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation. The current trial status is completed. This product is registered under clinical trial identifier NCT01931839. Target conditions include Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation.
What happened to similar drugs?
20 of 20 similar drugs in Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation were approved
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01931839 | Phase 3 | Completed |
Competing Products
20 competing products in Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation